Allergy & Immunology
What can we expect from first-generation COVID-19 vaccines?
22 Sep, 2020 | 10:02h | UTCWhat can we expect from first-generation COVID-19 vaccines? – The Lancet
Commentary on Twitter
We need to calibrate our expectations for the 1st generation of #SARSCoV2 vaccines https://t.co/QTJbyOd9xQ @TheLancet by @gmleunghku and Malik Peiris @hkumed Pe-covid normalcy is not near. pic.twitter.com/Y15TqfoRlf
— Eric Topol (@EricTopol) September 21, 2020
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
Covid-19: Do many people have pre-existing immunity?
18 Sep, 2020 | 09:41h | UTCCovid-19: Do many people have pre-existing immunity? – The BMJ
Commentary on Twitter
It seemed a truth universally acknowledged that the human population had no pre-existing immunity to SARS-CoV-2, but is that actually the case? Peter Doshi explores the emerging research on immunological responseshttps://t.co/6LYRjxlWBQ
— The BMJ (@bmj_latest) September 17, 2020
Change in antibodies to SARS-CoV-2 over 60 days among health care personnel
18 Sep, 2020 | 09:32h | UTC
Commentary on Twitter
In this cohort study, anti–SARS-CoV-2 antibodies decreased over 60d in HCWs w 58% becoming seronegative. The results suggest that x-sectional seroprevalence studies may underestimate rates of prior infections because Abs may only be transiently detectable https://t.co/IHgURuDJYm
— JAMA (@JAMA_current) September 18, 2020
[Press release – not published yet] Eli Lilly reports first, promising results for an antibody against COVID-19
17 Sep, 2020 | 09:28h | UTCEli Lilly reports first, promising results for an antibody against COVID-19 – Science
Press release: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
Multisystem effects of COVID-19: A concise review for practitioners
16 Sep, 2020 | 09:14h | UTCMultisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine
The lasting misery of coronavirus long-haulers
15 Sep, 2020 | 09:05h | UTCThe lasting misery of coronavirus long-haulers – Nature
Viewpoint: COVID-19 and the path to immunity
14 Sep, 2020 | 01:20h | UTCCOVID-19 and the Path to Immunity – JAMA
Commentary on Twitter
Declines in SARSCoV2 IgG neutralizing Abs raise concerns of susceptibility to reinfection. But acute Ab levels always decline post-infection, and Ab recall responses come from a pool of long-lived memory B cells https://t.co/geGOQkhdw2
— JAMA (@JAMA_current) September 12, 2020
COVID-19 herd immunity: Where are we?
14 Sep, 2020 | 01:18h | UTCCOVID-19 herd immunity: where are we? – Nature Reviews Immunology
Commentary on Twitter
This is one of the most succinct and best written short pieces on herd immunity, what it is and where we are heading with #COVID19.
If not comfortable with math, just get through the first sentences and it’s worth continuing the read. https://t.co/1F3MuQWkfc
— Michael Mina (@michaelmina_lab) September 13, 2020
The underdog coronavirus vaccines that the world will need if front runners stumble
11 Sep, 2020 | 01:20h | UTCThe underdog coronavirus vaccines that the world will need if front runners stumble – Nature
A leading coronavirus vaccine trial is on hold: Scientists react
10 Sep, 2020 | 09:43h | UTCA leading coronavirus vaccine trial is on hold: scientists react – Nature
Opinion: Halting the Oxford vaccine trial doesn’t mean it’s not safe – it shows they’re following the right process
10 Sep, 2020 | 09:42h | UTC
‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency
10 Sep, 2020 | 09:40h | UTC
Commentary on Twitter
Opinion: "In the middle of a pandemic — when the whole world, literally, is hoping a useful vaccine is on the horizon — everyone was left to guess what went wrong and what it might mean," @Pharmalot writes. https://t.co/jOpMyxC1dQ
— STAT (@statnews) September 9, 2020
AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.
9 Sep, 2020 | 09:45h | UTC
Commentary on Twitter
BREAKING: AstraZeneca's #Covid19 vaccine trials have been paused as the company investigates a serious adverse event the occurred in the UK. Not clear if the unexplained illness is linked to the vaccine, or what it was. https://t.co/wGqvvXIBTD
— Helen Branswell (@HelenBranswell) September 8, 2020
[Preprint] Randomized trial: Convalescent plasma not associated with improved outcomes in Covid-19
9 Sep, 2020 | 09:41h | UTC
Commentary on Twitter
Convalescent Plasma Randomized Controlled Trial (PLACID Trial) in the Management of Moderate #COVID19 (pre-print)
👉 “not associated with reduction in mortality or progression to severe COVID-19”
Link: https://t.co/2ZXnfemsas@GermHunterMD @MackayIM @CT_Bergstrom #IDTwitter pic.twitter.com/yZuOxVhbjL
— Alvin (@alvie_barr) September 8, 2020
Perspective: “When will WE have a vaccine?” — understanding questions and answers about Covid-19 vaccination
9 Sep, 2020 | 09:37h | UTC
Commentary on Twitter
People inquiring about Covid-19 vaccines often want to know when the public can be confident that available vaccines are safe and effective, when a vaccine will be available to people like them, and when uptake will be high enough to enable a return to prepandemic life. #COVID19
— NEJM (@NEJM) September 8, 2020
The coronavirus is mutating — does it matter?
9 Sep, 2020 | 09:35h | UTCThe coronavirus is mutating — does it matter? – Nature
The immunology of multisystem inflammatory syndrome in children with COVID-19
9 Sep, 2020 | 09:33h | UTCThe Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 – Cell
An ethical framework for global vaccine allocation
8 Sep, 2020 | 01:24h | UTCAn ethical framework for global vaccine allocation – Science
Commentary: Who should get the COVID-19 vaccine first? – University of Pennsylvania School of Medicine
Commentaries on Twitter
How would #COVID19 vaccines be distributed fairly across the globe once they are made available? Prominent philosophers and bioethicists outline the "Fair Priority Model", a 3-phase plan for vaccine distribution in @ScienceMagazine. https://t.co/1gdErzkRRh
— Stanford Ethics (@StanfordEthics) September 7, 2020
A new, three-phase plan for vaccine distribution for #COVID19—called the Fair Priority Model—is “the best embodiment of the ethical values of limiting harms…and recognizing equal concern for all people,” argues this #SciMagPolicyForum. Learn more: https://t.co/WKMvqKgDjl
— Science Magazine (@ScienceMagazine) September 7, 2020
WHO: Emergency use approval is a “temporary solution,” countries should wait for large clinical trials to finish to roll out a COVID-19 vaccine en masse
8 Sep, 2020 | 01:21h | UTC
Evolution of the COVID-19 vaccine development landscape
8 Sep, 2020 | 01:18h | UTCEvolution of the COVID-19 vaccine development landscape – Nature Reviews Drug Discovery
COVID-19 is, in the end, an endothelial disease
8 Sep, 2020 | 01:11h | UTCCOVID-19 is, in the end, an endothelial disease – European Heart Journal
Commentary on Twitter
COVID as an infectious disease of the “endothelium”, the lining of blood vessels, transmitted pre-sympyomatically. Explains the sepsis syndrome; explains the clotting/bleeding; explains the kidney failure.
What a nasty, nasty disease.https://t.co/5hlfL5Iik9
— David Fisman (@DFisman) September 7, 2020
Post-COVID syndrome severely damages children’s hearts; ‘immense inflammation’ causing cardiac blood vessel dilation
6 Sep, 2020 | 22:03h | UTCOriginal Study: Multisystem inflammatory syndrome in children: A systematic review – EClinicalMedicine
Commentary on Twitter
#COVID19 Multisystem inflammatory syndrome in children: A systematic review
An abnormal echocardiograph was observed in 314 of 581 patients (54·0%) with depressed ejection fraction (45·1%, n = 262 of 581) comprising the most common aberrancy.https://t.co/JqgETbH3DL pic.twitter.com/GqYtvGy0oP
— EPIDATUM (@epidatum) September 5, 2020
Does the COVID-19 cytokine storm exist?
6 Sep, 2020 | 21:55h | UTCDoes the COVID-19 cytokine storm exist? – Radboud University Medical Center
Original Study: Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions – JAMA
Commentary on Twitter
Study suggests #COVID19 may not be characterized by cytokine storm. Whether anticytokine therapies will benefit patients with COVID-19 remains to be determined https://t.co/alyFUwCYRC
— JAMA (@JAMA_current) September 4, 2020
Russian coronavirus vaccine results have been published
6 Sep, 2020 | 21:48h | UTCCommentaries: COVID-19 vaccines: early success and remaining challenges – The Lancet AND The Russian vaccine for COVID-19 – The Lancet Respiratory Medicine AND Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine – News Medical / The Lancet AND Russian coronavirus vaccine results have been published – here’s what they reveal – The Conversation
Commentary on Twitter
NEW—Preliminary results from Russian trials find that #COVID19 vaccine candidates led to no serious adverse events and elicit antibody response https://t.co/jGUwQa8oNd
Thread (1/8) pic.twitter.com/NWBpWDvUK3
— The Lancet (@TheLancet) September 4, 2020